News Column

New Conjugate Vaccines Findings Reported from Group Health Research Institute

May 26, 2014



By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating from Seattle, Washington, by NewsRx correspondents, research stated, "Streptococcus pneumoniae is a major cause of morbidity and mortality among adults 50 years of age and older in the United States. Pneumococcal conjugate vaccines are efficacious against pneumococcal disease in children and may also offer advantages in adults."

Our news editors obtained a quote from the research from Group Health Research Institute, "We performed a randomized, modified double-blind trial that compared a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in 831 pneumococcal vaccine naive adults 60-64 years of age. An additional group of 403 adults 50-59 years of age received open-label PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured at baseline, and at 1 month and 1 year after vaccination. In the randomized trial, the month 1 post-vaccination OPA geometric mean titers in the PCV13 group were statistically significantly higher than in the PPSV23 group for 8 of the 12 serotypes common to both vaccines and for serotype 6A, a serotype unique to PCV13, and were comparable for the other 4 common serotypes. The immune response to PCV13 was generally greater in adults 50-59 years of age compared to adults 60-64 years of age. OPA titers declined from 1 month to 1 year after PCV13 administration but remained higher than pre-vaccination baseline titers."

According to the news editors, the research concluded: "PCV13 induces a greater functional immune response than PPSV23 for the majority of serotypes covered by PCV13, suggesting that PCV13 could offer immunological advantages over PPSV23 for prevention of vaccine-type pneumococcal infection."

For more information on this research see: Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine, 2013;31(35):3577-84. (Elsevier - www.elsevier.com; Vaccine - www.journals.elsevier.com/vaccine)

The news editors report that additional information may be obtained by contacting L.A. Jackson, Group Health Research Institute, Seattle, Washington, United States. Additional authors for this research include A. Gurtman, M. van Cleeff, K.U. Jansen, D. Jayawardene, C. Devlin, D.A. Scott, E.A. Emini, W.C. Gruber and B. Schmoele-Thoma (see also Biotechnology).

Keywords for this news article include: Biotechnology, Seattle, Washington, Vaccination, Immunization, United States, Conjugate Vaccines, Synthetic Vaccines, Biological Products, Pneumococcal Disease, Public Health Practice, Pneumococcal Infections, Streptococcal Infections, North and Central America, Clinical Trials and Studies, Communicable Disease Control.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters